{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:14:36Z","timestamp":1761920076130,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["unrestricted grant"],"award-info":[{"award-number":["unrestricted grant"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s11481-015-9646-5","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T04:34:46Z","timestamp":1447994086000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)"],"prefix":"10.1007","volume":"11","author":[{"name":"GRAID investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S.","family":"Rommer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Freivogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Proft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U. K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"issue":"1","key":"9646_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2014.02.007","volume":"51","author":"SJ Beres","year":"2014","unstructured":"Beres SJ, Graves J, Waubant E (2014) Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 51(1):114\u2013118","journal-title":"Pediatr Neurol"},{"key":"9646_CR2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2165\/11585230-000000000-00000","volume":"70","author":"A Boster","year":"2010","unstructured":"Boster A, Ankeny DP, Racke MK (2010) The potential role of B cell-targeted therapies in multiple sclerosis. Drugs 70:2343\u20132356","journal-title":"Drugs"},{"issue":"5 Suppl 85","key":"9646_CR3","first-page":"S-163","volume":"32","author":"L Carmona","year":"2014","unstructured":"Carmona L, de la Vega M, Ranza R, Casado G, Titton DC, Descalzo M\u00c1, G\u00f3mez-Reino J (2014) BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol 32(5 Suppl 85):S-163\u2013S-167","journal-title":"Clin Exp Rheumatol"},{"issue":"9648","key":"9646_CR4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502\u20131517","journal-title":"Lancet"},{"issue":"7","key":"9646_CR5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270\u20131272","journal-title":"Neurology"},{"key":"9646_CR6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbadis.2010.07.020","volume":"1812","author":"AH Cross","year":"2011","unstructured":"Cross AH, Waubant E (2011) MS and the B cell controversy. Biochim Biophys Acta 1812:231\u2013238","journal-title":"Biochim Biophys Acta"},{"key":"9646_CR7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/1471-2407-14-870","volume":"14","author":"L Eberst","year":"2014","unstructured":"Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I (2014) The off-label use of targeted therapies in sarcomas: the OUTC\u2019S program. BMC Cancer 14:870. doi: 10.1186\/1471-2407-14-870","journal-title":"BMC Cancer"},{"issue":"5","key":"9646_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/1744-9987.12176","volume":"18","author":"J Ehler","year":"2014","unstructured":"Ehler J, Koball S, Sauer M, Hickstein H, Mitzner S, Benecke R, Zettl UK (2014) Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Ther Apher Dial 18(5):489\u2013496","journal-title":"Ther Apher Dial"},{"issue":"5","key":"9646_CR9","first-page":"653","volume":"32","author":"P Emery","year":"2014","unstructured":"Emery P, Gallo G, Boyd H, Morgan CL, Currie CJ, Poole CD, Nab HW (2014) Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 32(5):653\u2013660","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"9646_CR10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688","journal-title":"N Engl J Med"},{"issue":"4","key":"9646_CR11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460\u2013471","journal-title":"Ann Neurol"},{"key":"9646_CR12","volume":"12","author":"D He","year":"2013","unstructured":"He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (2013) Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 12, CD009130","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"9646_CR13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443\u20131448","journal-title":"Arch Neurol"},{"key":"9646_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, M\u00fcnch C, Winkelmann A, Zettl UUK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. doi: 10.1186\/1742-2094-9-14","journal-title":"J Neuroinflammation"},{"issue":"2","key":"9646_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176(2):149\u2013164","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"9646_CR16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110\u20131117","journal-title":"JAMA Neurol"},{"issue":"199","key":"9646_CR17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ane.12424","volume":"132","author":"N Koch-Henriksen","year":"2015","unstructured":"Koch-Henriksen N, Magyari M, Laursen B (2015) Registers of multiple sclerosis in Denmark. Acta Neurol Scand 132(199):4\u201310. doi: 10.1111\/ane.12424","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"9646_CR18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","volume":"36","author":"M Krumbholz","year":"2014","unstructured":"Krumbholz M, Meinl E (2014) B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 36(3):339\u2013350","journal-title":"Semin Immunopathol"},{"key":"9646_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-444-52001-2.00002-9","volume":"122","author":"A Kutzelnigg","year":"2014","unstructured":"Kutzelnigg A, Lassmann H (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 122:15\u201358","journal-title":"Handb Clin Neurol"},{"key":"9646_CR20","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"issue":"4","key":"9646_CR21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907\u2013911","journal-title":"Neurology"},{"issue":"9","key":"9646_CR22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ni1507","volume":"8","author":"HF McFarland","year":"2007","unstructured":"McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8(9):913\u2013919","journal-title":"Nat Immunol"},{"issue":"2","key":"9646_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62(2):258\u2013264","journal-title":"Arch Neurol"},{"issue":"23","key":"9646_CR24","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","volume":"74","author":"RT Naismith","year":"2010","unstructured":"Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74(23):1860\u20131867","journal-title":"Neurology"},{"issue":"13","key":"9646_CR25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938\u2013952","journal-title":"N Engl J Med"},{"issue":"15","key":"9646_CR26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310\u20131315","journal-title":"Neurology"},{"issue":"6","key":"9646_CR27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O\u2019Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol 58(6):840\u2013846","journal-title":"Ann Neurol"},{"issue":"3","key":"9646_CR28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-013-0233-x","volume":"15","author":"PS Rommer","year":"2013","unstructured":"Rommer PS, St\u00fcve O (2013) Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol 15(3):241\u2013258","journal-title":"Curr Treat Options Neurol"},{"key":"9646_CR29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/11589390-000000000-00000","volume":"25","author":"PS Rommer","year":"2011","unstructured":"Rommer PS, Patejdl R, Winkelman A, Benecke R, Zettl UK (2011) Rituximab for secondary progressive multiple sclerosis: a case series. CNS Drugs 25:607\u2013613","journal-title":"CNS Drugs"},{"issue":"29","key":"9646_CR30","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.2174\/138161212802502125","volume":"18","author":"PS Rommer","year":"2012","unstructured":"Rommer PS, Patejdl R, Zettl UK (2012) Monoclonal antibodies in the treatment of neuroimmunological diseases. Curr Pharm Des 18(29):4498\u20134507","journal-title":"Curr Pharm Des"},{"issue":"3","key":"9646_CR31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","volume":"175","author":"PS Rommer","year":"2014","unstructured":"Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, St\u00fcve O (2014) Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 175(3):397\u2013407","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"9646_CR32","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, K\u00f6tter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, M\u00fcller-Ladner U, K\u00f6nig R, Fiehn C, Burgwinkel P, Budde K, S\u00f6rensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, D\u00f6rner T, GRAID investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9646_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, K\u00fcmpfel T, Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1\u201316","journal-title":"J Neurol"},{"issue":"9894","key":"9646_CR34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382(9894):819\u2013831","journal-title":"Lancet"},{"key":"9646_CR35","first-page":"19","volume":"15","author":"E Waubant","year":"2008","unstructured":"Waubant E (2008) Spotlight on anti-CD20. Int MS J 15:19\u201325","journal-title":"Int MS J"},{"issue":"5","key":"9646_CR36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53(5):1107\u20131114","journal-title":"Neurology"},{"issue":"10","key":"9646_CR37","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485\u20131489","journal-title":"Neurology"},{"issue":"3","key":"9646_CR38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.autrev.2011.05.008","volume":"11","author":"UK Zettl","year":"2012","unstructured":"Zettl UK, St\u00fcve O, Patejdl R (2012) Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11(3):167\u2013173","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-015-9646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11481-015-9646-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-015-9646-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:06:33Z","timestamp":1559390793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11481-015-9646-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["9646"],"URL":"https:\/\/doi.org\/10.1007\/s11481-015-9646-5","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"type":"print","value":"1557-1890"},{"type":"electronic","value":"1557-1904"}],"subject":[],"published":{"date-parts":[[2015,11,20]]}}}